NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
Clinical Trials
51 trialsNCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03872388 2024-10-02
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT02229149 2022-12-02
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
US Oncology Research
Phase 2 Terminated
NCT05091528 2022-08-18
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
Silverback Therapeutics
Phase 1/2 Terminated
NCT00508274 2021-09-21
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
Novartis
Phase 3 Terminated
NCT04031885 2021-08-24
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Eli Lilly and Company
Phase 4 Terminated
NCT03858972 2021-07-30
CONTESSA 2
Odonate Therapeutics, Inc.
Phase 2 Terminated
NCT04274933 2020-10-29
A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
AbbVie
Phase 1 Terminated
NCT00437294 2020-08-10
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT02294786 2019-07-15
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Novartis
Phase 2 Terminated
NCT00462865 2019-04-09
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Brown University
Phase 2 Terminated
NCT00130507 2019-02-26
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT00434941 2019-02-21
Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT02297230 2018-10-15
Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
NYU Langone Health
Phase 1/2 Terminated
NCT01887288 2018-02-22
Capecitabine With Digoxin for Metastatic Breast Cancer
Western Regional Medical Center
Phase 2 Terminated
NCT02120417 2018-02-13
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Incyte Corporation
Phase 2 Terminated
NCT01655992 2018-01-23
A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)
Fudan University
Phase 3 Terminated
NCT00684216 2017-09-14
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT00194792 2017-07-11
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
University of Washington
Phase 2 Terminated
NCT00496366 2017-03-21
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT02213744 2017-01-06
HERMIONE
Merrimack Pharmaceuticals
Phase 2/3 Terminated
NCT00977379 2016-11-15
XERAD
Hoffmann-La Roche
Phase 2 Terminated
NCT00845910 2016-11-02
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT01132664 2016-08-17
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Novartis
Phase 1/2 Terminated
NCT01069796 2016-03-17
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT00546364 2016-03-10
IXTEND
R-Pharm
Phase 2 Terminated
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT00347438 2015-12-14
Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer
University of Chicago
Phase 2 Terminated
NCT00235235 2015-12-09
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
Hoosier Cancer Research Network
Terminated
NCT00148720 2015-11-11
Capecitabine in Women With Operable Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01067989 2015-07-08
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT01290718 2014-12-17
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
Hoffmann-La Roche
Phase 2 Terminated
NCT01238029 2014-11-21
CELAVIE
Sponsor GmbH
Phase 1 Terminated
NCT00082095 2014-10-09
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00570908 2014-09-18
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Baylor Breast Care Center
Phase 2 Terminated
NCT00576901 2014-08-11
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Hoffmann-La Roche
Phase 2 Terminated
NCT01233505 2014-04-02
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01200212 2013-05-22
TABEA
GBG Forschungs GmbH
Phase 3 Terminated
NCT00440622 2013-02-13
Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Phase 3 Terminated
NCT00227656 2012-12-11
Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00049660 2012-07-18
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Terminated
NCT00479856 2012-06-05
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00473005 2012-05-28
Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
Stanford University
Phase 1 Terminated
NCT00657137 2012-03-15
APRiCOT-B
Tragara Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00193102 2011-05-03
Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00216073 2011-05-02
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated